Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

The Lancet Oncology

Volumn 11, Issue 11, 2010, Pages 1086-1095

  Delforge, Michel ^a   Bladé, Joan ^b   Dimopoulos, Meletios A ^c   Facon, Thierry ^d   Kropff, Martin ^e   Ludwig, Heinz ^f   Palumbo, Antonio ^g   Van Damme, Philip ^a   San Miguel, Jesús F ^h   Sonneveld, Pieter ⁱ  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF ATHENS   (Greece)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f Wilhelminenspital   (Austria)

^g UNIVERSITY OF TURIN   (Italy)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BORTEZOMIB; CARFILZOMIB; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; GLUTAMINE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; LEVACECARNINE; MELPHALAN; MYELIN ASSOCIATED GLYCOPROTEIN; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE; VITAMIN B GROUP;

ATAXIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTONOMIC DYSFUNCTION; BRADYCARDIA; CELL SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CYTOKINE PRODUCTION; DEMYELINATION; DENERVATION; DIARRHEA; DISEASE PREDISPOSITION; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYPESTHESIA; HYPOTHYROIDISM; IMMUNOMODULATION; IMPOTENCE; INCIDENCE; LOW DRUG DOSE; MOTOR DYSFUNCTION; MOTOR NEUROPATHY; MULTIPLE MYELOMA; MUSCLE CRAMP; NERVE CONDUCTION; NERVE FIBER; NEUROPATHIC PAIN; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PATHOPHYSIOLOGY; PERIKARYON; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PHOCOMELIA; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SCHWANN CELL; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SEXUAL DYSFUNCTION; SKIN BIOPSY; SKIN TINGLING; SPINAL GANGLION; TERATOGENICITY; TREATMENT DURATION; TREMOR; VITAMIN SUPPLEMENTATION; WEAKNESS;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; INCIDENCE; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RISK ASSESSMENT; RISK FACTORS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 78049528177     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70068-1     Document Type: Review

References (75)

1. Kyle RA, Rajkumar SV Multiple myeloma. Blood 2008, 111:2962-2972.
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565-1571.
3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
4. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004, 127:165-172.
5. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
6. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
7. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
8. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
9. Antoine J-C, Camdessanche J-P Peripheral nervous system involvement in patients with cancer. Lancet Neurol 2007, 6:75-86.
10. Kelly JJ The evaluation of peripheral neuropathy. Part I: clinical and laboratory evidence. Rev Neurol Dis 2004, 1:133-140.
11. Windebank AJ, Grisold W Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008, 13:27-46.
12. Hafstrom T Polyneuropathy after neurosedyn (thalidomide) and its prognosis. Acta Neurol Scand 1967, 43:1-41.
13. Fullerton PM, O'Sullivan DJ Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry 1968, 31:543-551.
14. Ghobrial IM, Rajkumar SV Management of thalidomide toxicity. J Support Oncol 2003, 1:194-205.
15. Cata JP, Weng H-R, Burton AW, et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007, 8:296-306.
16. Chaudhry V, Cornblath DR, Corse A, et al. Thalidomide-induced neuropathy. Neurology 2002, 59:1872-1875.
17. Tariman JD, Love G, McCullagh E, Sandifer S Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 2008, 12:29-36.
18. Argyriou AA, Iconomou G, Kalofonos HP Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008, 112:1593-1599.
19. Coutsouvelis J, Corallo CE Thalidomide-induced bradycardia and its management. Med J Aust 2004, 180:366-367.
20. Murphy PT, O'Donnell JR Thalidomide induced impotence in male hematology patients: a common but ignored complication?. Haematologica 2007, 92:1440.
21. Fullerton PM, Kremer M Neuropathy after intake of thalidomide (distaval). BMJ 1961, 2:855-858.
22. Rajkumar SV Thalidomide: tragic past and promising future. Mayo Clin Proc 2004, 79:899-903.
23. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001, 12:991-995.
24. Prince HM, Mileshkin L, Roberts A, et al. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res 2005, 11:5504-5514.
25. Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005, 74:212-216.
26. Feyler S, Rawstron A, Jackson G, et al. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Br J Haematol 2007, 139:429-433.
27. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006, 132:584-593.
28. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008, 26:2171-2177.
29. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370:1209-1218.
30. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009, 27:3664-3670.
31. Harousseau JL, Mathiot C, Attal M, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial. J Clin Oncol 2008, 26. abstr 8505.
32. Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004, 79:875-882.
33. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009, 27:1788-1793.
34. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006, 354:1021-1030.
35. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006, 367:825-831.
36. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006, 24:4507-4514.
37. Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 2007, 69:573-581.
38. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006, 108:3458-3464.
39. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007, 25:4459-4465.
40. Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009, 146:164-170.
41. Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009, 27:5713-5719.
42. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113-3120.
43. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009, 144:895-903.
44. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009, 21:3518-3525.
45. Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymphoma Myeloma 2008, 8:140-145.
46. Cavo M, Tacchetti P, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Blood 2008, 112. abstr 158.
47. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008, 13:275-282.
48. Harousseau JL, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone (VD) versus reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Blood 2009, 114. abstr 354.
49. Vij R, Wang L, Orlowski RZ, et al. Carfilzomib (CFZ), a novel proteasome inhibitor for relapsed or refractory multiple myeloma, is associated with minimal peripheral neuropathic effects. Blood 2009, 114. abstr 430.
50. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone (pom/dex) is highly effective therapy in relapsed multiple myeloma. J Clin Oncol 2009, 27:5008-5014.
51. Silberman J, Lonial S Review of peripheral neuropathy in plasma cell disorders. Hematol Oncol 2008, 26:55-65.
52. Harland CC, Steventon GB, Marsden JR Thalidomide-induced neuropathy and genetic differences in drug metabolism. Eur J Clin Pharmacol 1995, 49:1-6.
53. Ricci DS, Favis R, Sun Y, et al. Pharmacogenomic (PGx) analysis of bortezomib-associated peripheral neuropathy in the phase 3 VISTA trial of bortezomib plus melphalan-prednisone versus melphalan-prednisone in multiple myeloma. Blood 2009, 114. abstr 3875.
54. Laaksonen S, Remes K, Koskela K, Voipio-Pulkki L-M, Falck B Thalidomide therapy and polyneuropathy in myeloma patients. Electromyogr Clin Neurophysiol 2005, 45:75-86.
55. McBride WG Fetal nerve cell degeneration produced by thalidomide in rabbits. Teratology 1974, 10:283-291.
56. Aronson IK, Yu R, West DP, Van den Broek H, Antel J Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures. Arch Dermatol 1984, 120:1466-1470.
57. Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 2004, 109:188-193.
58. Silverman L, Csizmadia V, Brewer K, Simpson C, Alden C Proteasome inhibitor associated neuropathy is mechanism based. Blood 2008, 112. abstr 2646.
59. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007, 204:317-325.
60. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008, 26:4784-4790.
61. Fernyhough P, Smith DR, Schapansky J, et al. Activation of nuclear factor-(kappa)B via endogenous tumor necrosis factor (alpha) regulates survival of axotomized adult sensory neurons. J Neurosci 2005, 25:1682-1690.
62. Schwartzman RJ, Chevlen E, Bengtson K, et al. Thalidomide has activity in treating complex regional pain syndrome (multiple letters). Arch Intern Med 2003, 163:1487-1488.
63. Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of velcade (PS-341/Bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005, 65:3828-3836.
64. Bennett GJ, Paice JA Peripheral neuropathy: experimental findings, clinical approaches. J Support Oncol 2007, 5:61-63.
65. Poruchynsky MS, Sackett DL, Robey RW, et al. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 2008, 7:940-949.
66. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004, 62:2291-2293.
67. Berenson JB, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005, 104:2141-2148.
68. Gay F, Bringhen S, Genuardi M, et al. The weekly infusion of bortezomib reduces peripheral neuropathy. Blood 2009, 114. abstr 3887.
69. Zara G, Ermani M, Rondinone R, Arienti S, Doria A Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry 2008, 79:1258-1261.
70. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11:570-579.
71. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: A definition for clinical research-report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005, 64:199-207.
72. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003, 61:1297-1300.
73. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008, 44:1507-1515.
74. Perrone G, Hideshima T, Ikeda H, et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 2009, 23:1679-1686.
75. Colvin LA, Johnson PRE, Mitchell R, Fleetwood-Walker SM, Fallon M From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol. J Clin Oncol 2008, 26:4519-4520.